Greenwich LifeSciences has announced a strategic extension of its Flamingo-01 clinical trial into Belgium, marking a significant step forward in its commitment to advancing innovative therapies across Europe. This expansion enables the trial to leverage Belgium’s robust medical infrastructure and experienced research institutions, thereby accelerating patient recruitment and data collection. The move underscores Greenwich’s dedication to fostering transnational research partnerships that enrich clinical outcomes and enhance the scientific community’s collective understanding of the treatment’s efficacy.

Key advantages driving this expansion include:

  • Access to diverse patient populations that improve the trial’s demographic representation.
  • Collaboration with leading Belgian clinical centers, boosting trial management…